Currently Viewing:
Newsroom
Currently Reading
A Significant Unmet Mental Health Care Need Exists for Patients With COPD
August 25, 2019 – Kelly Davio
Medicaid Expansion Linked to Increased HIV Testing
August 24, 2019 – Jaime Rosenberg
5 Things to Look for at the European Society of Cardiology 2019 Congress
August 23, 2019 – Mary Caffrey
Phase I Pancreatic Cancer Trial Identifies Effective Combination Treatment
August 23, 2019 – Alison Rodriguez
AJMC® in the Press, August 23, 2019
August 23, 2019 – AJMC Staff
Fatal AEs Associated With Alemtuzumab for MS May Occur More Frequently Than Previously Thought
August 23, 2019 – Laura Joszt
What We're Reading: ACA Plan Offerings Expand; Combo Pill Cuts CV Events; Biosimilar Savings
August 23, 2019 – AJMC Staff
This Week in Managed Care: August 23, 2019
August 23, 2019
HHS Proposes Easing Privacy Restrictions for Patients With History of Substance Use Disorder
August 22, 2019 – Jaime Rosenberg

New Blood Biomarker Offers Earlier Detection of Pancreatic Cancer

Alison Rodriguez
A new blood biomarker demonstrates its ability to detect pancreatic cancer earlier, which can lead to better treatment and outcomes, according to a study published in Science Translational Medicine.
A new blood biomarker demonstrates its ability to detect pancreatic cancer earlier, which can lead to better treatment and outcomes, according to a study published in Science Translational Medicine.

In the United States over 53,000 people are diagnosed with pancreatic cancer per year, but most are not diagnosed until an advanced stage when tumors can no longer be surgically removed. Ken Zaret, PhD, of the University of Pennsylvania School of Medicine, and Gloria Petersen, PhD, from the Mayo Clinic, led the team that found a pair of biomarkers that can be used to detect pancreatic cancer sooner.

"Starting with our cell model that mimics human pancreatic cancer progression, we identified released proteins, then tested and validated a subset of these proteins as potential plasma biomarkers of this cancer," stated Zaret in a press release. 

The researchers predict that the presence of the biomarker will be tested through blood drawn from pancreatic cancer patients and those at a high risk of developing the disease.

"Early detection of cancer has had a critical influence on lessening the impact of many types of cancer, including breast, colon, and cervical cancer," said Robert Vonderheide, MD, DPhil, director of the the University of Pennsylvania’s Abramson Cancer Center, in the press statement. "Having a biomarker test for this disease could dramatically alter the outlook for these patients."

The biomarker was developed by reprogramming late-stage human cancer cells to a stem cell state, which forces the reprogrammed cells to an early cancerous stage and reveals blood biomarkers of the disease. Plasma thrombospondin-2 (THBS2) was found to be the best biomarker candidate because when screened against 746 cancer and control plasma samples, the blood levels of THBS2 combined with the later-stage biomarker CA19-9 were reliable at identifying pancreatic cancer.

"Positive results for THBS2 or CA19-9 concentrations in the blood consistently and correctly identified all stages of the cancer," Zaret concluded. "Notably, THBS2 concentrations combined with CA19-9 identified early stages better than any other known method." 

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up